Arcturus Therapeutics Changes Independent Auditor

TL;DR

Arcturus swapped PwC for EY as their auditor. No fireworks, just a change.

AI Summary

Arcturus Therapeutics Holdings Inc. announced on April 5, 2024, a change in its certifying accountant. The company has dismissed PricewaterhouseCoopers LLP and engaged Ernst & Young LLP as its new independent registered public accounting firm. This change was approved by the Audit Committee of the Board of Directors.

Why It Matters

A change in auditor can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting, which investors will monitor.

Risk Assessment

Risk Level: low — The filing solely reports a change in the company's independent auditor, which is a routine administrative event.

Key Players & Entities

• Arcturus Therapeutics Holdings Inc. (company) — Registrant
• PricewaterhouseCoopers LLP (company) — Former certifying accountant
• Ernst & Young LLP (company) — New certifying accountant
• April 5, 2024 (date) — Date of report and change

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share ARCT The NASDAQ Stock Mar

Filing Documents

• e663496_8k-arct.htm (8-K) — 29KB
• e663496_ex16-1.htm (EX-16.1) — 2KB
• 0001193805-24-000505.txt ( ) — 201KB
• arct-20240405.xsd (EX-101.SCH) — 3KB
• arct-20240405_lab.xml (EX-101.LAB) — 33KB
• arct-20240405_pre.xml (EX-101.PRE) — 22KB
• e663496_8k-arct_htm.xml (XML) — 4KB

01

Item 4.01 Changes in Registrant's Certifying Accountant. (a) Dismissal of Previous Independent Registered Public Accounting Firm On April 5, 2024, the audit committee of the board of directors (the " Audit Committee ") of Arcturus Therapeutics Holdings Inc.'s (the " Company " or " Arcturus ") authorized the dismissal of Ernst & Young LLP (" EY ") as the Company's independent registered public accounting firm, and EY was dismissed as the Company's independent registered public accounting firm as of such date. EY served as the Company's independent registered public accounting firm for the fiscal years ended December 31, 2023 and 2022 and the subsequent periods through April 5, 2024. EY's report on the Company's consolidated financial statements as of and for the years ended December 31, 2023 and 2022 did not contain an adverse opinion or disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles. EY's report on the Company's internal control over financial report as of December 31, 2023 contained an adverse opinion. During the Company's two most recent fiscal years ended December 31, 2023 and 2022 and the subsequent interim period through April 5, 2024: (1) there were no disagreements between the Company and EY on any matters of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of EY, would have caused them to make reference to the subject matter of the disagreements in connection with their opinion on the Company's consolidated financial statements; and (2) there were no "reportable events" (as described in Item 304(a)(1)(v) of Regulation S-K), except that, as previously disclosed in the Company's 2023 annual report filed on Form 10-K, management identified material weaknesses in the Company's internal control over financial reporting for the fiscal year ended December 31, 2023 related to the Company

Financial Statements and Exhibits

Financial Statements and Exhibits . (d) Exhibits Exhibit No. Description 16.1 Letter from Ernst & Young LLP to the Securities and Exchange Commission dated April 5, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Arcturus Therapeutics Holdings Inc. Date: April 5, 2024 By: /s/ Joseph E. Payne Name: Joseph E. Payne Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR